Target intelligence / Profile preview

Mitochondrial ribosomal protein L57 pseudogene 7 (MRPL57P7)

Target
MRPL57P7
Molecular classification
Other (Pseudogene; not a protein, enzyme, receptor, transporter, ion channel or transcription factor), Homology: Related by sequence to mitochondrial ribosomal protein L57, a component of the mitochondrial ribosome large subunit, Family: Mitochondrial ribosomal protein pseudogenes
01

Overview

Mitochondrial ribosomal protein L57 pseudogene 7 (MRPL57P7) is a processed pseudogene by sequence similarity to mitochondrial ribosomal protein L57. Pseudogenes such as MRPL57P7 lack coding potential due to gene structure mutations and are not translated into proteins. MRPL57P7 is one of several pseudogenes related to MRPL57 found in the human genome. Unlike functional MRPL57, which is a nuclear-encoded protein essential for mitochondrial ribosome structure and function, MRPL57P7 does not contribute to mitochondrial protein synthesis or cellular processes. It has no established biological or disease implications and is not considered a therapeutic target. For research on mitochondrial ribosomal proteins as targets, focus should be on functional genes such as MRPL57, which participates in mitochondrial protein translation and may have roles in cancer and metabolic diseases as reviewed in recent literature. MRPL57 and its family members contribute to mitochondrial function but MRPL57P7 is not involved in these processes due to its pseudogene status. If the intention is to identify a proteinaceous drug target or biomarker, MRPL57P7 is not suitable and the focus should shift to functional, protein-coding members of the mitochondrial ribosomal protein family.

Other names
MRP63P7Mitochondrial ribosomal protein 63 pseudogene 7MRPL57P7MRP63 pseudogene 7
02

Mechanism of action

None (No known mechanism, as it does not encode a functional protein)

03

Biological functions

None (Pseudogenes do not have direct protein-mediated biological functions; no evidence is available that MRPL57P7 is transcribed or translated into a functional product)
04

Disease associations

None known (No evidence links this pseudogene specifically to disease etiology, pathology, or drug response)
05

Safety considerations

None (Pseudogenes themselves do not pose safety concerns; functional mitochondrial ribosomal proteins, in contrast, can be involved in disease and drug toxicity, but this is not relevant for MRPL57P7)
06

Interacting drugs

None (Drugs do not target pseudogenes, only functional proteins/enzymes/receptors)
07

Biomarkers

None (Pseudogene status makes it ineligible as a biomarker)

Beyond the preview

Go deeper on Mitochondrial ribosomal protein L57 pseudogene 7 (MRPL57P7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial ribosomal protein L57 pseudogene 7 (MRPL57P7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call